Ixekizumab Linked to Low Risk of Major Cardiovascular Events in Psoriatic Patients
An analysis of patients with psoriasis, PsA, or axSpA show risk of MACE with ixekizumab is consistently low.
Ruben Queiro Mark Lebwohl Eli Lilly Icahn School Of Medicine At Mount Sinai Maui Derm Colorado Springs
Source: hcplive.com